Liraglutide vs Orforglipron

Liraglutide is a GLP-1 receptor agonist already approved by the FDA, sold under the brand names Saxenda and Victoza, and used to treat type 2 diabetes, obesity, and to reduce cardiovascular risk. Orforglipron is a new, non-peptide GLP-1 receptor agonist taken as a pill, but it is still in development and has not yet been approved by the FDA for any use.

AI summary of the sources below.